Navigation Links
Cardiome anuncia su presencia en el Congreso ESC 2013 en Ámsterdam
Date:8/29/2013

5;l es el paciente adecuado para este fármaco?
13:50 - 14:00: Conclusión y declaraciones de cierre

Un webcast del simposio estará disponible al público en el sitio web 365 del Congreso ESC (http://congress365.escardio.org/home.aspx) hasta septiembre de 2014.

Acerca de Cardiome Pharma Corp.

Cardiome Pharma Corp. es una compañía biofarmacéutica dedicada al descubrimiento, desarrollo y comercializacion de nuevas terapias que mejorarán la salud de los pacientes en todo el mundo. Cardiome tiene un producto comercializado, BRINAVESS[TM] (vernakalant IV), aprobado en Europa y otros territorios para la rápida conversión de fibrilación atrial de aparición reciente para el ritmo sinusal en adultos.

Cardiome cotiza en NASDAQ Capital Market (CRME) y la Toronto Stock Exchange (COM). Para más información, visite nuestro sitio web en http://www.cardiome.com.

Nota cautelar sobre las declaraciones prospectivas
Determinadas declaraciones de este comunicado contienen declaraciones prospectivas dentro de la Private Securities Litigation Reform Act de 1995 o información prospectiva dentro de la legislación de valores canadiense aplicable que no se basan en hechos históricos, incluyendo, entre otras, declaraciones que contienen las palabras "cree", "podría", "planea", "podrá", "estima", "continúa", "anticipa", "pretende", "espera" y expresiones similares. Las declaraciones prospectivas podrían implicar, entre otros, comentarios con respecto a nuestros objetivos y prioridades para el resto de 2013 y más allá, nuestras estrategias o acciones futuras, nuestros objetivos, expectativas para nuestra condición financiera y los resultados de, o perspectiva para, nuestras operaciones, investigación y desarrollo y d
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CardioMEMS CFO, Daniel H. Bauer, Honored with a CFO of the Year Award by the Atlanta Business Chronicle
2. CardioMEMS Vice President - Information Systems, Richard Powers, and Chairman of the Board, John Huntz, Selected as Finalists for Prestigious Awards
3. CardioMEMS, Inc. wins 2012 Intel Innovation Award
4. CardioMEMS Named as a Finalist for Intel Innovation Award
5. CryoLife anuncia el primer implante europeo del injerto HeRO
6. ReSearch Pharmaceutical Services anuncia a Marc Wolff como responsable financiero
7. Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2
8. Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva
9. Novo progresso anunciado na ação judicial contra a Assembleia do Prêmio Nobel movida pelo Dr. Rongxiang Xu
10. GenScript anuncia un programa conjunto con Open Monoclonal Technology, Inc.
11. GenScript anuncia una muestra itinerante conjunta con Open Monoclonal Technology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015  Par Pharmaceutical Companies, ... conference call on Friday, March 13, 2015 at ... operations for the fourth quarter and full year ... and currently makes certain financial information available to ... and Exchange Commission and will make certain other ...
(Date:3/6/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... milestone payment from Biogen Idec related to advancing the ... in infants with spinal muscular atrophy (SMA).  ... is a randomized, double-blind, sham-procedure controlled thirteen month ... study will evaluate the efficacy and safety of a ...
(Date:3/5/2015)... March 5, 2015 WuXi PharmaTech (Cayman) Inc. ... capability and technology platform company serving the pharmaceutical, biotechnology, ... the United States, today announced its financial results for ... Fourth-Quarter 2014 Highlights , Net Revenues Increased ... Laboratory Services Net Revenues Grew 17.7% Year Over Year ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22
... presented at the 2008 iSBTc Annual Meeting -, ... a.m. ET to discuss,results -, BRANFORD, Conn., Nov. ... preliminary data from an ongoing Phase II,trial of CR011-vcMMAE, ... patients with unresectable Stage III or Stage IV melanoma.,Dr. ...
... Clinical Study of Paliperidone ER in this Under-Studied ... with schizoaffective,disorder receiving paliperidone extended release tablets (paliperidone ... their symptoms, according,to a new study presented today ... San Diego, Calif.(1) In addition, safety findings were ...
Cached Medicine Technology:CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6
(Date:3/6/2015)... OR (PRWEB) March 06, 2015 Ticket Down ... in Portland, Oregon at the Moda Center. After ... superstar Garth Brooks is showing no signs of letting up ... the country legend and his wife, Trisha Yearwood, to venues ... would be bringing their critically acclaimed tour to the Moda ...
(Date:3/6/2015)... March 06, 2015 Ticket Down is a ... popular ticket exchange has extended their customer appreciation discount code ... Bridge, West Yorkshire England and he began his career in ... the past couple of years Ed Sheeran has become a ... Sheeran is on stage he is having the time of ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
(Date:3/6/2015)... Many patients with knee osteoarthritis have continued ... (or someone you know) have chronic pain and problems ... interested in the ACT-OA clinical trial. , Kevin ... is one of fifteen physicians in the U.S. to ... as part of a new, multi-site, double blind, placebo-controlled ...
(Date:3/6/2015)... Raleigh, NC (PRWEB) March 06, 2015 In ... percentage of Polish mesothelioma patients reported that shoulder pain was ... full story on its website. Click here to read ... in Warsaw analyzed the medical records of 49 mesothelioma ... of them reported that it was shoulder pain that first ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2
... of genetics, environment caused mice to develop disease, study finds ... with mice, scientists have found a bacteria living in the ... rheumatoid arthritis. , The gut of all mammals is populated ... are essential for developing a normal immune system. But some ...
... Announcing a new Web ... to improve the look and strength of your abdominal muscles and improve overall health. Get ... site. , ... A new Web site has been developed to help anyone get in shape. If you ...
... ... to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA in Bayside, ... ... is pleased to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA ...
... ... Guidance Based on Experience at Pfizer, Merck, Medtronic, GTx, Johnson & Johnson, and the University ... ... 2010 -- To support its focus on regulatory compliance in the life sciences, openQ has ...
... now new areas in which whole body magnetic resonance imaging ... Deutsches rzteblatt International ( Dtsch Arztebl Int 2010; ... of possible uses, together with the limits of this radiation-free ... routine use in hospitals, as the procedure takes less than ...
... is an uncommon benign neoplasm with locally aggressive behavior but ... a 14-year-old patient with clinical presentations of abdominal pain and ... research article to be published on June 7, 2010 in ... A research team led by Professor Ko from Chang Gung ...
Cached Medicine News:Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 2Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 3Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 3Health News:openQ Announces the Formation of a Compliance Advisory Board 2Health News:openQ Announces the Formation of a Compliance Advisory Board 3
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
... The CoaguChek S System offers ... in just one minute requiring only ... enable you to provide more comprehensive ... with each patient. The CoaguChek S ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: